About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
exaly
›
Institutions
›
National Taiwan University Hospital
›
Department of Oncology
›
Top Articles
Department of Oncology
National Taiwan University Hospital
1.6K
Articles
47.8K
Citations
3.2
avg. Impact Factor
92
h-index
Most Cited Articles of Department of Oncology in 2016
Title
Journal
Year
Citations
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
Journal of Thoracic Oncology
2016
169
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Oncotarget
2016
165
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
Liver Cancer
2016
80
LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
Journal of Thoracic Oncology
2016
79
A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy
Biomaterials
2016
78
Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma
Clinical Chemistry
2016
69
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
Science Translational Medicine
2016
58
Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles
ACS Applied Materials & Interfaces
2016
55
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
Journal of Thoracic Oncology
2016
55
Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer
Oncotarget
2016
53
Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study
Journal of the National Cancer Institute
2016
48
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations
Journal of Thoracic Oncology
2016
46
Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials
Liver Cancer
2016
43
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
Annals of Oncology
2016
39
Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells
Cancer Letters
2016
37
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.
Journal of Clinical Oncology
2016
37
MicroRNA-146a-5p Negatively Regulates Pro-Inflammatory Cytokine Secretion and Cell Activation in Lipopolysaccharide Stimulated Human Hepatic Stellate Cells through Inhibition of Toll-Like Receptor 4 Signaling Pathways
International Journal of Molecular Sciences
2016
35
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
Journal of Biomedical Science
2016
35
Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection
Annals of Hematology
2016
33
Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study
BMC Cancer
2016
32
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
Cancer Letters
2016
31
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression
Clinical Cancer Research
2016
28
Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells
Rna
2016
26
RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy
American Journal of Surgical Pathology
2016
26
Adverse prognosis and distinct progression patterns after concurrent chemoradiotherapy for glioblastoma with synchronous subventricular zone and corpus callosum invasion
Radiotherapy and Oncology
2016
25
Schools/Departments
The list of schools/departments is not comprehensive since it is common to drop the department in the affiliation.
site/software ©
exaly
; All materials licenced under
CC by-SA
.